Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 238

1.
2.

Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization.

Warkentin TE, Cook RJ, Marder VJ, Greinacher A.

J Thromb Haemost. 2010 Mar;8(3):504-12. doi: 10.1111/j.1538-7836.2009.03735.x. Epub 2009 Dec 24.

3.

Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive.

Selleng S, Malowsky B, Strobel U, Wessel A, Ittermann T, Wollert HG, Warkentin TE, Greinacher A.

J Thromb Haemost. 2010 Jan;8(1):30-6. doi: 10.1111/j.1538-7836.2009.03626.x. Epub 2009 Sep 28.

4.

Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.

Warkentin TE, Cook RJ, Marder VJ, Sheppard JA, Moore JC, Eriksson BI, Greinacher A, Kelton JG.

Blood. 2005 Dec 1;106(12):3791-6. Epub 2005 Aug 18.

5.

Anti-platelet factor 4/heparin antibodies in patients with impaired graft function after liver transplantation.

Bakchoul T, Assfalg V, Zöllner H, Evert M, Novotny A, Matevossian E, Friess H, Hartmann D, Hron G, Althaus K, Greinacher A, Hüser N.

J Thromb Haemost. 2014 Jun;12(6):871-8. doi: 10.1111/jth.12569.

6.

Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays.

Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG.

J Thromb Haemost. 2008 Aug;6(8):1304-12. doi: 10.1111/j.1538-7836.2008.03025.x. Epub 2008 May 17.

7.

Effect of anti-platelet factor-4/heparin antibody induction on early saphenous vein graft occlusion after coronary artery bypass surgery.

Gluckman TJ, Segal JB, Schulman SP, Shapiro EP, Kickler TS, Prechel MM, Conte JV, Walenga JM, Shafique I, Rade JJ.

J Thromb Haemost. 2009 Sep;7(9):1457-64. doi: 10.1111/j.1538-7836.2009.03526.x. Epub 2009 Jun 23.

8.

Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies.

Greinacher A, Gopinadhan M, Günther JU, Omer-Adam MA, Strobel U, Warkentin TE, Papastavrou G, Weitschies W, Helm CA.

Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2386-93. Epub 2006 Jul 27.

9.

Incidence and clinical relevance of anti-platelet factor 4/heparin antibodies before cardiac surgery.

Selleng S, Malowsky B, Itterman T, Bagemühl J, Wessel A, Wollert HG, Warkentin TE, Greinacher A.

Am Heart J. 2010 Aug;160(2):362-9. doi: 10.1016/j.ahj.2010.05.026.

PMID:
20691844
10.

Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay.

Althaus K, Strobel U, Warkentin TE, Greinacher A.

Thromb Res. 2011 Sep;128(3):256-60. doi: 10.1016/j.thromres.2011.05.003. Epub 2011 May 28.

PMID:
21620439
11.

IgG classification of anti-PF4/heparin antibodies to identify patients with heparin-induced thrombocytopenia during mechanical circulatory support.

Schenk S, El-Banayosy A, Morshuis M, Arusoglu L, Eichler P, Lubenow N, Tenderich G, Koerfer R, Greinacher A, Prohaska W.

J Thromb Haemost. 2007 Feb;5(2):235-41. Epub 2006 Oct 31.

12.

A diagnosis of heparin-induced thrombocytopenia with combined clinical and laboratory methods in cardiothoracic surgical intensive care unit patients.

Demma LJ, Winkler AM, Levy JH.

Anesth Analg. 2011 Oct;113(4):697-702. doi: 10.1213/ANE.0b013e3182297031. Epub 2011 Jul 25.

PMID:
21788317
13.

Heparin/PF4 antibodies formation after heparin treatment: temporal aspects and long-term follow-up.

Mattioli AV, Bonetti L, Zennaro M, Ambrosio G, Mattioli G.

Am Heart J. 2009 Mar;157(3):589-95. doi: 10.1016/j.ahj.2008.11.007. Epub 2009 Jan 13.

PMID:
19249435
14.

Evaluation of a new automated panel of assays for the detection of anti-PF4/heparin antibodies in patients suspected of having heparin-induced thrombocytopenia.

Legnani C, Cini M, Pili C, Boggian O, Frascaro M, Palareti G.

Thromb Haemost. 2010 Aug;104(2):402-9. doi: 10.1160/TH10-01-0002. Epub 2010 Jun 10.

PMID:
20539902
15.

Distinguishing between anti-platelet factor 4/heparin antibodies that can and cannot cause heparin-induced thrombocytopenia.

Nazi I, Arnold DM, Warkentin TE, Smith JW, Staibano P, Kelton JG.

J Thromb Haemost. 2015 Oct;13(10):1900-7. doi: 10.1111/jth.13066. Epub 2015 Aug 29.

PMID:
26291604
16.

The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia.

Lubenow N, Hinz P, Thomaschewski S, Lietz T, Vogler M, Ladwig A, Jünger M, Nauck M, Schellong S, Wander K, Engel G, Ekkernkamp A, Greinacher A.

Blood. 2010 Mar 4;115(9):1797-803. doi: 10.1182/blood-2009-07-231506. Epub 2009 Nov 20.

17.

Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia.

Fabris F, Luzzatto G, Soini B, Ramon R, Scandellari R, Randi ML, Girolami A.

J Intern Med. 2002 Aug;252(2):149-54.

18.

Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.

Greinacher A, Alban S, Omer-Adam MA, Weitschies W, Warkentin TE.

Thromb Res. 2008;122(2):211-20. doi: 10.1016/j.thromres.2007.11.007. Epub 2008 Feb 8.

PMID:
18262226
19.

Heparin-platelet factor 4 antibodies in intensive care patients: an observational seroprevalence study.

Levine RL, Hergenroeder GW, Francis JL, Miller CC, Hursting MJ.

J Thromb Thrombolysis. 2010 Aug;30(2):142-8. doi: 10.1007/s11239-009-0425-0.

PMID:
19911252
20.

IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics.

Motokawa S, Torigoshi T, Maeda Y, Maeda K, Jiuchi Y, Yamaguchi T, Someya S, Shindo H, Migita K.

BMC Musculoskelet Disord. 2011 Jan 24;12:22. doi: 10.1186/1471-2474-12-22.

Supplemental Content

Support Center